Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience.

Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. In this article we review the current evidence and experience of its use.

Therapeutic advances in urology. 2018 Sep 26*** epublish ***

Sara J Allison, William Gibson

Division of Geriatric and Stroke Medicine, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK., Division of Geriatric Medicine, University of Alberta, 1-198 Clinical Sciences Building, 11350 83Ave, Edmonton, Alberta, T6G 2P4, Canada.